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Abstract: This review focuses on the critical pathophysiological significance of capsaicin-sensitive trigeminal primary af-
ferent neurons in the mechanisms of neurovascular responses in animal models of cranial pain and their possible relevance 
for primary headaches. In the rat dura mater, neurogenic sensory vasodilator responses elicited by activation of the tran-
sient receptor potential vanilloid type 1 (TRPV1) receptor are mediated by the release of calcitonin gene-related peptide 
(CGRP) from sensory nerves, which suggests that similar mechanisms may operate in man during migraine attacks, when 
an increased concentration of CGRP is measured in the jugular venous blood. Capsaicin-sensitive trigeminal afferent 
nerves also contribute to the vasodilatory responses induced by the activation of protease-activated receptor 2 (PAR-2), 
which involves the release of CGRP from capsaicin-sensitive afferent nerves. Importantly, the activation of PAR-2 has 
been shown to sensitize the TRPV1 receptor. Demonstration of the colocalization of PAR-2 and TRPV1 receptors in the 
meningeal axons lends further support to this mechanism. Neurogenic vasodilatory responses mediated by capsaicin-
sensitive afferent nerves may serve a protective function via the elimination of inflammatory mediators from the tissue, a 
mechanism which may play a role in the resolution of headaches. Pathological conditions such as diabetes mellitus may 
compromise this protective mechanism through decreases in the expression of TRPV1 and the release of CGRP. These 
observations indicate an important role of capsaicin-sensitive meningeal afferent nerves in the pathophysiology of head-
aches and suggest that pharmacological manipulation of the TRPV1 receptor may offer a promising approach to the man-
agement of headaches. 
Keywords: Calcitonin gene-related peptide, capsaicin, headache, meningeal blood flow, nociception, transient receptor poten-
tial vanilloid type 1 receptor. 
Despite the many years of research and the availability of 
clinically effective drugs for headache therapy, the pathoge-
netic mechanisms of primary headaches are still unclear. 
Although current opinion holds that migraine attacks start in 
the brain, clinical and experimental evidence indicates that 
the headache phase begins with the activation of peripheral 
nociceptors [1-3]. As the major pain-sensitive intracranial 
structure, the dura mater encephali has become the preferen-
tial target of studies on the peripheral mechanisms of menin-
geal nociception and headache. It is innervated by trigeminal 
sensory nerve fibers which contain vasoactive neuropeptides 
such as calcitonin gene-related peptide (CGRP), substance P 
(SP) and neurokinin A (NKA) [4-6]. Most of these peptider-
gic nerve fibers are closely associated with blood vessels and 
comprise the trigeminovascular system of the meninges [5, 
7]. Recent studies indicate that both vascular and neural 
mechanisms may activate trigeminal perivascular afferent 
nerves. Once activated, trigeminal afferents convey nocicep-
tive information to the central nervous system (CNS) and, 
through the release of vasoactive peptides from their periph-
eral terminals, they also promote a sterile neurogenic in-
flammatory process in the tissue [8]. Meningeal neurogenic 
inflammation has been proposed as an important mechanism 
in the generation of pain and changes in meningeal blood 
flow in headache patients [9]. Clinical observations support 
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the significance of neuropeptide release in the pathophysiol-
ogy of primary headaches. Blood collected from the jugular 
vein on the affected side during migraine and cluster head-
ache attacks contains increased levels of the vasodilator neu-
ropeptide CGRP [10, 11]. The activation of chemo/cap- 
saicin-sensitive primary sensory neurons expressing the tran-
sient receptor potential vanilloid type 1 (TRPV1) receptors 
plays a fundamental role in the generation of the neurogenic 
inflammatory response of the dura mater [12]. For studies of 
the mechanisms of trigeminal nociceptor activation and 
changes in dural blood flow, experimental animal models of 
meningeal nociception have been developed. 
In this review, we focus on evidence supporting the piv-
otal role of trigeminal paravascular chemosensitive nocicep-
tors, which express the TRPV1 receptors, in nociceptive and 
vascular processes relevant to the pathomechanisms of head-
aches. In different organs, chemosensitive nerve fibers play a 
key role in the transmission/modulation of pain elicited by 
noxious heat, acidic pH or inflammatory mediators [13-18]. 
Activation of capsaicin-sensitive nerves may also play a cen-
tral role in headache mechanisms. Since neurovascular re-
sponses are considered to be significant pathophysiological 
processes involved in the generation, maintenance and/or 
relief of headache pain, recognition of the physiological role 
of meningeal capsaicin-sensitive nerve fibers and clarifica-
tion of the factors and pathophysiological conditions that 
alter the function or sensitivity of these nociceptive nerves 
may provide a suitable approach to an understanding of the 
pathophysiology of primary and other types of headaches. To 
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evaluate the possible significance of chemosensitive noci-
ceptive afferents in the generation, maintenance and relief of 
headache pain, we will discuss the evidence for 1) the exis-
tence of chemosensitive nerves in the dura mater, 2) the acti-
vation of these nerves by capsaicin and other vanilloids, and 
3) vascular reactions mediated by the activation of TRPV1, 
protease-activated receptor 2 (PAR-2) and histamine recep-
tors. 
I. CAPSAICIN-SENSITIVE SENSORY NERVE FI-
BERS IN THE DURA MATER ENCEPHALI AND 
THEIR PATHOPHYSIOLOGICAL SIGNIFICANCE 
1. Activation of Chemosensitive Primary Sensory Neu-
rons Participate in the Central Transmission of Head-
ache Pain 
In consequence of the morphological and functional simi-
larities shared by the human and rodent dura mater en-
cephali, the rat dura mater is a suitable animal model for 
study of the pathophysiological mechanisms of headaches. 
The blood supply of the rat dura mater is provided by the 
middle meningeal artery. The dura mater is richly innervated 
by myelinated (A type) and unmyelinated (C type) nerve 
fibers. The number of C-fibers with a putative nociceptor 
function is approximately three times that of the A-fibers 
[19]. Immunohistochemical investigations have identified 
two different types of nerve plexuses with regard to their 
localization in the rat dura mater [20]. One plexus was found 
to be situated within the dural connective tissue, and the 
other in the perivascular region. The terminals of meningeal 
afferent A- and C-fibers are unencapsulated free nerve end-
ings [5, 19]. Innervation of the meningeal tissue has three 
sources; most nerve fibers have a sympathetic or afferent 
origin, while parasympathetic nerves in the dura mater are 
rare. 
Although all three divisions (ophthalmic, maxillary and 
mandibular) of the trigeminal nerve contribute to the sensory 
innervation of the dura mater, the cell bodies supplying the 
supratentorial part of the dura mater are located in the oph-
thalmic division of the trigeminal ganglion. Recent studies in 
our laboratory have revealed that a significant population of 
the meningeal sensory nerves is capsaicin-sensitive [12]. 
Capsaicin-sensitive primary sensory neurons comprise a 
morphologically, neurochemically and functionally well-
characterized population of sensory ganglion cells [21-23] 
which express the TRPV1 receptor [18, 24]. A huge body of 
evidence indicates that capsaicin-sensitive sensory ganglion 
neurons participate in the transmission of chemogenic and 
inflammatory pain [22, 25] and through the release of 
vasoactive peptides (CGRP, SP and NKA) from their periph-
eral terminals they also play a fundamental role in local 
regulatory functions of the innervated tissue, including vaso-
dilatation and plasma extravasation [26]. Electron micro-
scopic and immunohistochemical studies have demonstrated 
the existence of functional capsaicin-sensitive nerves in the 
rat dura mater [12, 27]. A rich TRPV1-immunoreactive in-
nervation of the dura mater has been revealed, with the nerve 
fibers forming bundles or running as single axons in the 
dural connective tissue and in a paravascular localization 
along blood vessels. During the past few years, experimental 
results published by several other research groups have con-
firmed our findings and extended our knowledge on the 
morphology and function of meningeal nerves which express 
the TRPV1 receptor [28-30].  
Pathophysiological events leading to the sensitization of 
meningeal chemosensitive nerves (peripheral sensitization) 
may be responsible for the intracranial hypersensitivity ob-
served in migraine and other types of headaches; otherwise 
innocuous stimuli or even pulsatile changes in meningeal 
blood flow and/or intracranial pressure may activate the tri-
geminal nociceptive pathway [31]. Prolonged activation of 
the primary sensory neurons may also alter the excitability of 
second-order neurons in the caudal trigeminal nuclear com-
plex leading to central sensitization which, in turn, increases 
the intensity of pain transmission [32]. 
2. Activation of Chemosensitive Primary Sensory Neu-
rons Induces Vascular Reactions in the Dura Mater 
The activation of capsaicin-sensitive meningeal afferents 
produces TRPV1 receptor-mediated vasodilatory responses 
through the release of CGRP in the rat dura mater [12]. In an 
open cranial window preparation, topical application of cap-
saicin onto the dura mater induces dose-dependent changes 
in meningeal blood flow. Chemical stimulation of the men-
ingeal sensory nerve fibers with capsaicin in low concentra-
tions (50-100 nM) elicits moderate but significant vasodila-
tory responses, as assessed by laser Doppler flowmetry. Cap-
saicin-induced vasoconstriction observed by topical applica-
tion of capsaicin in higher concentrations is generally re-
garded as resulting from a direct vascular action of capsaicin 
independent of neural activation [33, 34]. Vasodilator re-
sponses to capsaicin are inhibited or even completely abol-
ished by systemic pretreatment of the animals with capsaicin 
in a dose that results in a profound depletion of sensory neu-
ropeptides [22, 35-37]. These findings suggest that sensory 
nerve-mediated vasodilatation in the dura mater involves 
capsaicin-sensitive afferents. This is supported by findings 
demonstrating that capsaicin-induced vasodilatation is sig-
nificantly inhibited by local pretreatment of the dura mater 
with a TRPV1 receptor antagonist, capsazepine and the 
CGRP receptor antagonist CGRP8-37. Activation of the noci-
ceptive pathway and meningeal vasodilatation mediated by 
CGRP appear to be important mechanisms in the patho-
physiology of primary headaches. Studies in migraineurs 
have lent support to this by indicating increased levels of 
CGRP in the jugular venous blood during headache attacks 
[11, 38]. Blockade of the CGRP receptors with non-peptide 
CGRP receptor antagonists has proved to be a very promis-
ing option for the treatment of primary headaches in clinical 
trials [39]. Although vasodilatation may not be significantly 
implicated in the generation of pain in meningeal pain-
sensitive structures [40], changes in meningeal blood flow 
are implicated in the pathophysiology of headaches. Impor-
tantly, the accumulation of algogenic and vasoactive agents 
during headache attacks may impede meningeal tissue integ-
rity [41, 42]. Neurogenic sensory vasodilatation which de-
velops concommitantly with the activation of meningeal 
chemosensitive nociceptive fibres may serve a homeostatic 
function in the dura mater. An increase in blood flow may 
exert a beneficial effect by removing inflammatory metabo-
lites which induce or aggravate headache attacks [43]. Phar-
macological interventions through drugs which proved to be 
effective in headache therapy may interfere with the physio-
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logical defence mechanism conferred by neurogenic sensory 
vasodilatation. However, drugs such as triptans, CGRP- and 
TRPV1 receptor antagonists may produce effective pain re-
lief by reducing transmitter release from the central terminals 
of nociceptive trigeminovascular nerves.  
The pathophysiological significance of plasma extravasa-
tion, another component of neurogenic inflammation, is 
more controversial in the meningeal tissue. In rats, the level 
of dural plasma extravasation was increased after systemic 
administration of capsaicin or electrical stimulation of the 
trigeminal ganglion, and this increase was abolished by neo-
natal capsaicin treatment [44]. Although some clinical stud-
ies have indicated increased contents of plasma SP and 
CGRP even during headache-free periods in migraineurs 
[45], clinical trials involving the treatment of patients with 
the SP antagonist RPR100893 during migraine attacks 
proved completely ineffective [46]. These clinical and ex-
perimental observations indicate that the increase in vascular 
permeability induced by the release of SP from the stimu-
lated trigeminal sensory nerves is probably not of major sig-
nificance as regards the pathophysiology of headaches. 
3. Role of Histamine in the Neural and Vascular Reac-
tions of the Dura Mater 
In the dura mater, similarly as in other tissues, the activa-
tion of capsaicin-sensitive afferent nerves results in the re-
lease of vasodilator neuropeptides [47-49]. Besides their 
direct vascular effects, CGRP and SP released from stimu-
lated nerves initiate a cascade of events that result in the de-
granulation of mast cells and the activation of platelets. Mast 
cells containing vasoactive substances have been observed in 
close proximity to SP-containing nerve fibers. Electrical 
stimulation of the trigeminal ganglion leads to mast cell acti-
vation and degranulation in the dura mater [48]. SP and 
CGRP release histamine from rat dural mast cells, which 
suggests an additional pathway for the possible involvement 
of these neuropeptides in intracranial vasoregulation and 
neurogenic inflammation, besides their direct effects on 
blood vessels [50]. 
The vascular effects of histamine in the dura mater are 
mediated by the H1 and H2 receptors of arterial vessels. 
While H2 receptors on smooth muscle cells mediate vaso-
dilatation, the activation of smooth muscle H1 receptors 
causes vasoconstriction. The vasodilatory effect of H2 recep-
tors predominates when histamine is applied locally onto the 
dura mater, i.e. when its concentration is high in the perivas-
cular compartment, where the mast cells are located. In con-
trast, high histamine levels in the blood stream activate endo-
thelial H1 receptors which promote endothelial nitric oxide 
synthase (NOS) activity to produce nitric oxide (NO), which 
diffuses to the smooth muscle cells and causes vasorelaxa-
tion [51, 52]. 
The communication between sensory nerve endings and 
mast cells is bidirectional in most tissues. Sensory nerve 
terminals may be sensitized or even activated by histamine 
[53, 54]. Histamine-induced neuropeptide release can be 
modified by presynaptic H3 receptors present on sensory 
nerve endings. In the dura mater, the bidirectional communi-
cation between these structures has not yet been proved; in 
an in vitro dura mater preparation, CGRP stimulated the re-
lease of histamine, while, reciprocally, histamine was not 
able to release CGRP from meningeal afferents even under 
the blockade of presynaptic H3 receptors [55, 56]. 
Although the release of histamine from activated mast 
cells and the consequent activation of peptidergic nocicep-
tive nerve endings are significant components of neurogenic 
inflammation in the dura mater, the role of histamine in the 
pathophysiology of headaches is still a subject of consider-
able debate. The experimental headache induced by the i.v. 
infusion of histamine is in many ways similar to the pulsat-
ing headache seen in migraine. Moreover, migraine patients 
seem to be more susceptible than controls to histamine-
induced headache [57]. Hence, antihistamines combined 
with other antiinflammatory medications are recommended 
in certain forms of headaches; as examples, measures to pre-
vent cluster headache and other headaches combined with 
allergic reactions include antihistamine therapy, but antihis-
tamines fail to alleviate pain during headache attacks [58, 
59].  
4. Activation of the Trigeminal-Parasympathetic Reflex  
Experimental findings have provided evidence of a neu-
ral basis for a trigeminal-parasympathetic reflex which ex-
plains meningeal vasodilatation during headaches and links 
increased neurometabolic activity with the transmission of 
headache pain by the trigeminal nerve [60]: an increase in 
cortical metabolic activity results in the release of neuro-
transmitters and metabolites into the extracellular and peri-
vascular spaces. Experimentally induced cortical spreading 
depression (CSD) which is regarded as an equivalent of the 
aura phase of migraine attack, is a condition that influences 
both neuronal activity and blood flow [61]. Neurotransmit-
ters and metabolites released by CSD activate or sensitize 
perivascular trigeminal afferents and transmit impulses cen-
trally to the trigeminal nucleus caudalis (TNC). Activation of 
the TNC also leads to stimulation of the superior salivatory 
nucleus and consequently parasympathetic efferents via the 
sphenopalatine ganglion. The activation of postganglionic 
parasympathetic fibers promotes meningeal vasodilatation by 
releasing vasoactive agents from their terminals, such as 
vasoactive intestinal polypeptide, NO or acetylcholine [60]. 
Capsaicin-sensitive trigeminal nerves may be sensitized by 
inflammatory mediators and tissue metabolites and this 
might form the structural basis of the trigeminal-parasy- 
mpathetic reflex whose activation results in the transmission 
of nociceptive stimuli and promotes parasympathetic menin-
geal vasodilatation. 
5. Neuron-glia Signaling in the Trigeminal Ganglion 
Migraine attack is thought to be initiated by peripheral 
sensitization of the nociceptive system, which results from 
the increased activity of trigeminal nociceptors. Peripheral 
sensitization is characterized by an increased level of neu-
ronal excitability and a lowering of the threshold for activa-
tion. Glial cells, earlier thought to serve only a supportive 
role, are now known to modulate the neuronal function and 
activity in the trigeminal ganglion directly [62]. 
Trigeminal ganglia comprise neurons and two types of 
glial cells, satellite cells and Schwann cells, which are asso-
ciated with nerve fibers and produce the myelin sheet. The 
cell bodies of the primary afferent neurons that convey sen-
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sory information from the periphery to the CNS are com-
pletely surrounded by satellite cells, while the Schwann cells 
are associated with neuronal processes that project both to 
the periphery and to the CNS. Morphological studies have 
shown that processes of glial cells lie in close proximity to 
the plasma membrane of neurons. It is now accepted that 
glial cells, which outnumber the neurons in trigeminal gan-
glia, influence neuronal activity directly by controlling the 
microenvironment in the ganglion [63, 64].  
Neuronal-glial cell communication via gap junctions is 
rapidly and markedly enhanced following the activation of 
nociceptive neurons by capsaicin [62]. Elevated gap junction 
activity is observed only between neurons and satellite glial 
cells, but not between Schwann cells. In vitro studies have 
provided evidence that CGRP release from neurons may 
activate adjacent satellite cells and promote the release of 
inflammatory cytokines. Increased levels of cytokines have 
been shown to result in local inflammatory reactions and 
modulation of the neuronal function [65, 66]. In this way, 
CGRP could function as a paracrine factor to stimulate 
nearby neurons and glial cells within a cluster and also cause 
excitation of more distant neurons and glia located in other 
clusters, thereby propagating an inflammatory signal across 
the entire ganglion. Patients with migraine headache often 
feel sinus pain and pressure, which involve the activation of 
sensory C-fibers in the maxillary region of the trigeminal 
ganglion. Such commonly reported symptoms associated 
with migraine headache may be explained by the propaga-
tion of inflammatory signals within the trigeminal ganglion. 
6. Neuron-glia Signaling in the Trigeminal Subnucleus 
Caudalis 
It is becoming increasingly evident that the cellular 
changes associated with the central sensitization of nocicep-
tive pathways are not restricted to neurons. Non-neuronal 
cell types, and particularly glial cells (mainly astrocytes and 
microglia) in the CNS are activated by inflammation or pe-
ripheral nerve injury and are involved in the transmission of 
nociceptive information and central sensitization. Astrocytes 
and microglia participate in neuronal sensitization by releas-
ing cytokines or glutamate, modifying synaptic transmission 
[67-69]. 
Recent studies have demonstrated that trigeminal central 
sensitization also involves glial activation [70]. Morphologi-
cal studies have revealed a close relationship between astro-
cytes and nerve endings in the subnucleus caudalis of the 
nucleus tractus spinalis nervi trigemini, suggesting that as-
trocytes may play a role in the transmission of nociceptive 
information. The morphological interrelationship between 
the astrocytes and the nerve endings in laminae I and II of 
the subnucleus caudalis has been identified by double-
labeling electron microscopic immunohistochemistry [71]. In 
a model of trigeminal central sensitization induced by the 
application of mustard oil to the rat tooth pulp, intrathecal 
administration of fluoroacetate (an inhibitor of the astroglial 
metabolic enzyme aconitase) markedly attenuated the in-
creases in receptive field size, the responses to noxious stim-
uli and the decrease in the threshold of neurons in the tri-
geminal subnucleus caudalis [72]. Furthermore, mustard oil-
induced central sensitization could be significantly attenu-
ated by the continuous intrathecal superfusion of methionine 
sulfoximine, an inhibitor of astroglial glutamine synthetase 
[73].  
 The glial mechanisms in trigeminal central sensitization 
most likely involve their interactions with the glutamatergic 
receptors. It has been demonstrated that astrocytes may in-
fluence the presynaptic terminals directly through the activa-
tion of presynaptic glutamatergic mechanisms by increasing 
the probability of neurotransmitter release from nerve termi-
nals and modulating synaptic transmission [74, 75]. The in-
volvement of NMDA receptors may, at least in part, be re-
lated with the phosphorylation mediated by interleukin-1 
receptor signaling. Tumor necrosis factor α produced by mi-
croglial cells also enhances synaptic efficacy by increasing 
the surface expression of AMPA receptors on cultured neu-
rons [76].  
Some experimental findings suggest that the involvement 
of glial cells in trigeminal central sensitization may also be 
related with the activation of purinergic receptors. It has 
been reported that ATP stimulates the release of brain-
derived neurotrophic factor from microglia, which causes a 
depolarizing shift in the anion reversal potential in spinal 
lamina I neurons [77]. The glial activation may additionally 
mediate the sensitization by controlling the local microcircu-
lation through purinergic receptors. It has been postulated 
that one of their physiological roles is to mediate vasodilata-
tion in response to increased neural activity during sensitiza-
tion [78]. 
II. PATHOPHYSIOLOGICAL CONDITIONS AFFECT-
ING THE ACTIVITY OF CAPSAICIN-SENSITIVE 
NERVES 
1. Conditions Impairing TRPV1-Mediated Nociceptive 
Responses 
Neuropathic changes that affect trigeminal nociceptive 
neurons may alter their function, initiating meningeal neuro-
genic inflammation and the transmission of pain impulses 
toward the CNS. Metabolic and inflammatory diseases or 
toxic effects of different drugs affect the functional integrity 
of sensory nerve fibers. By far the greatest number of clinical 
and experimental data is available on diabetic neuropathic 
alterations and their effects on headache conditions. 
Diabetic Neuropathy 
In humans diabetic neuropathy affects both myelinated 
and unmyelinated nerve fibers, which results in disturbances 
in autonomic, motor and sensory functions, including the 
sensation of pain [79-81]. Clinical observations indicate that 
diabetic patients suffer more than non-diabetics from head-
aches. The onset of migraine or tension-type headaches fre-
quently occurs concomitantly with the onset of diabetes mel-
litus. Increases in the frequency and duration of headache 
attacks have also been noted in patients with diabetes [82, 
83].  
Studies involving an established animal model of head-
aches have revealed that meningeal neurogenic sensory 
vasodilatation, elicited by activation of the TRPV1 receptors 
in intact rats, is absent in the dura mater of diabetic rats 6 
weeks after the induction of diabetes with streptozotocin. In 
vitro measurement of the capsaicin-induced release of CGRP 
revealed an attenuated peptide release from preparations of 
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the dura mater of diabetic rats. Treatment of diabetic rats 
with insulin restored both the vasodilatory response and the 
meningeal release of CGRP toward control levels. Dimin-
ished arterial smooth muscle sensitivity or an impairment of 
the endothelial function is unlikely to contribute to the reduc-
tion of neurogenic sensory vasodilatation at this stage of 
experimental diabetes mellitus, since changes were not ob-
served in the vasodilatory effects of CGRP, histamine and 
acetylcholine acting directly on the vascular smooth muscle 
or endothelial cells [27]. In diabetes, an insufficient vasodila-
tor function of the meningeal sensory nerves may result in 
disturbances of tissue homeostasis, e.g. through a reduced 
clearance of inflammatory mediators, ultimately inducing 
further activation and/or sensitization of meningeal nocicep-
tors and cranial pain. A dysfunction of paravascular pep-
tidergic afferent vasodilatory nerves may be implicated in 
the mechanisms which contribute to the increased incidence 
and severity of headaches in diabetic patients [82, 83]. 
2. Sensitization of Meningeal Chemosensitive Afferent 
Nerves 
Phosphorylation of the TRPV1 receptors on sensory nerve 
fibers increases the probability of the ion channel opening in 
response to heat, protons and endogenous ligands and may 
result in sensitization of the channel. Prostaglandin E2, 
bradykinin, nerve growth factor, ATP, glutamate, tryp-
sin/tryptase and prolactin are pro-inflammatory mediators 
that activate their receptors through activation of the phos-
pholipase C, phospholipase A2, adenylyl cyclase, protein 
kinase C and protein kinase A signaling pathways, leading to 
sensitization of the TRPV1 receptor via phosphorylation. 
Sensitization of the TRPV1 channels localized on capsaicin-
sensitive trigeminal sensory nerves seems to be a key 
mechanism in the pathophysiology of headaches [84, 85].  
Protease-activated Receptor-2 
Morphological findings have demonstrated that TRPV1 
receptors and a member of the protease-activated receptor 
(PAR) family, PAR-2, are co-localized in a significant popu-
lation of nerve fibers associated with blood vessels or run-
ning freely in the stroma of the dura mater [86]. Trypsin or 
mast cell tryptase cleaves and activates this G protein-
coupled receptor, which plays important roles in the re-
sponses to injury, inflammation and tissue repair [87, 88]. In 
the rat dura mater, activation of PAR-2 induces marked 
vasodilatation, which involves the release of CGRP from 
capsaicin-sensitive afferent nerves and the release of NO 
from endothelial cells. In an open cranial window prepara-
tion, pretreatment of the dura mater with the PAR-2 agonist 
peptide Ser–Leu–Ile–Gly–Arg–Leu–amide (SLIGRL-NH2) 
markedly enhanced the vasodilatory effect of capsaicin. 
These findings indicated that activation of PAR-2 may 
modulate the meningeal nociceptor function by initiating 
neuronal signaling mechanisms, leading to sensitization of 
the TRPV1 receptor expressed by capsaicin-sensitive affer-
ent nerves [86]. Under pathophysiological conditions, the 
release of neuropeptides from sensory nerves may degranu-
late mast cells, giving rise to further sensitization of cap-
saicin-sensitive trigeminal nerves by PAR-2. The develop-
ment of a vicious circle initiated by the release of CGRP 
and/or SP from capsaicin-sensitive trigeminal nerves may 
contribute significantly to the pathomechanisms of headaches. 
Ethanol 
Alcoholic drinks and other products containing alcohol 
may cause headaches in susceptible patients. The alcohol-
induced headache generally occurs 30-45 minutes after the 
consumption of alcohol, which corresponds to the time 
needed for complete absorption from the gastrointestinal 
tract. Alcoholic beverages also trigger migraine and cluster 
headache attacks [89]. Although alcohol may impair cerebral 
autoregulation and depresses the cerebral serotonin turnover, 
which may contribute to the pathomechanism of alcohol-
induced headaches [90], recent studies clarified a stimulat-
ing/sensitizing effect of ethanol on TRPV1 receptors of pri-
mary sensory neurons [91]. The intragastric administration 
of ethanol induced neurogenic inflammation in the dura ma-
ter of guinea pigs [92]. Both meningeal vasodilatation and 
the increased plasma extravasation of the dura mater were 
induced by the ingestion of ethanol, but these increases were 
reduced by pretreatment with the TRPV1 receptor antagonist 
capsazepine and antagonists for the CGRP and NK1 recep-
tors. In an in vitro preparation, ethanol-induced release of 
neuropeptides from the dura mater was abolished by Ca2+ 
removal, capsaicin pretreatment and the TRPV1 antagonist, 
capsazepine. The protein kinase C pathway has been re-
ported to contribute to the ethanol-induced sensitization of 
the TRPV1 receptor [91].  
Sensitization of Capsaicin-Sensitive Trigeminal Mecha-
nisms by Nitric Oxide  
As a potent vasodilator and an agent involved in the sen-
sitization of primary and secondary neurons of trigeminal 
pathways, NO has been suggested to contribute to the patho-
physiology of primary headaches [93]. Clinical studies have 
demonstrated that an NO donor such as glyceryl trinitrate 
(GTN) may trigger a migraine attack. In a pilot study ad-
ministration of an NOS inhibitor was effective in the treat-
ment of migraine headache. Some human studies have also 
indicated abnormalities in metabolites of NO in headache 
patients [94]. 
Animal studies have provided important data on the 
pathophysiological role of NO in trigeminovascular activa-
tion. Different forms of NOS have been demonstrated in 
endothelial cells, mast cells and some nerve fibers of the 
dura mater [95]. Enzyme activity has also been detected in 
some trigeminal ganglion cells and the TNC [96, 97]. Subcu-
taneous injection of GTN has been found to produce a sig-
nificant increase in NOS activity and c-fos protein-like im-
munoreactivity in the TNC [98] and brainstem nuclei [99] in 
rats. Following the infusion of GTN, the responses of neu-
rons to electrical stimulation of periorbital cutaneous nerves 
were potentiated and the thresholds for the activation of TNC 
neurons by stimulation of the dural afferents were reduced. 
Activation is thought to be mediated by an effect of NO on 
unmyelinated nociceptive trigeminal fibers, since it was 
abolished after capsaicin pretreatment [100]. The role of 
capsaicin-sensitive trigeminal nociceptors in NO-induced 
sensitization is further corroborated by the observation that 
an intradermal injection of capsaicin into the periorbital area 
increased the expression of c-fos in the TNC which was sig-
nificantly potentiated by GTN infusion [101]. Although the 
exact mechanism of NO-induced sensitization of capsaicin-
sensitive trigeminal neurons has not yet been elucidated, the 
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experimental data indicate a potentiating effect of NO on the 
release of vasodilator neuropeptides such as CGRP from 
primary sensory neurons [102].  
III. ENDOGENOUS LIGANDS ACTING ON THE 
TRPV1 RECEPTOR: ENDOVANILLOIDS 
Endovanilloids are endogenous ligands of the nonselec-
tive cation channel TRPV1 receptor [103]. It has been sug-
gested that, besides heat and low pH (< 4.3), TRPV1 recep-
tors are activated by certain arachidonic acid metabolites 
acting as endogenous ligands of the ion channel. To classify 
a molecule as an endovanilloid, the compound should be 
synthesized and released in sufficient amount to evoke a 
TRPV1-mediated response by direct activation of the chan-
nel. To control TRPV1 signaling, endovanilloids should be 
inactivated within a short time-span. As the binding site for 
an endogenous ligand acting on the TRPV1 receptor is intra-
cellular, it might be expected that endogenous ligands are 
produced intracellularly or transported into the cell. 
Arachidonylethanolamide (anandamide, AEA) is proba-
bly the most widely studied endogenous ligand in the tri-
geminal system that acts on both cannabinoid and TRPV1 
receptors. AEA is believed to be primarily an endogenous 
ligand to the cannabinoid receptors [104, 105] found in the 
central and peripheral nervous systems. Cannabinoid CB1 
receptors are localized on nerve fibers in the spinal trigemi-
nal tract and the spinal TNC [106]. In a study involving the 
use of intravital microscopy, AEA acted via the CB1 recep-
tor to inhibit the dural blood vessel dilatation brought about 
in the rat by electrical stimulation of the dura mater or the 
systemic administration of CGRP, capsaicin and NO [107]. 
AEA appears to act both presynaptically to prevent CGRP 
release from the trigeminal sensory nerves, and postsynapti-
cally to inhibit CGRP-induced NO release in the wall of the 
dural arteries. Besides acting at the CB1 receptor, AEA has 
been found to act as an agonist on the TRPV1 receptor [108], 
and it is able to activate sensory neurons via the TRPV1 re-
ceptor. AEA activates the TRPV1 receptor in a similar way 
to capsaicin, promoting the release of CGRP and causing 
dural vasodilatation [102]. This CGRP-induced vasodilata-
tion is in marked contrast to the inhibitory effects of AEA on 
neurogenic vasodilatation [107]. The dual effect of AEA on 
CGRP release mediated by different receptors on capsaicin-
sensitive nerve fibers may be an important regulatory 
mechanism affecting both pain transmission and blood flow 
changes in the meningeal tissues. The sensitivities of the 
TRPV1 and CB1 receptors for AEA on trigeminal neurons 
may differ, since the doses of AEA required to produce a 
maximal dilator response was much higher than that neces-
sary to inhibit neurogenically induced vasodilatation [109]. 
The interpretation of these experimental results is difficult 
since the i.v. administration of AEA had a significant impact 
on the systemic blood pressure of the experimental animals. 
Experimental studies clarifying the effects of topically ap-
plied AEA on the dura mater may provide more reliable data 
concerning the participation of TRPV1 and CB1 receptors in 
the activation of capsaicin-sensitive meningeal nerve fibers. 
Much less information is available on the possible roles of 
other endovanilloids on the activity of meningeal nociceptors 
and on blood flow. N-arachidonyl-dopamine (NADA) and 
N-oleoyl-dopamine (OLDA) have been identified as en-
dogenous compounds acting on both TRPV1 and CB1 recep-
tors, but OLDA proved to be much more selective for 
TRPV1 receptors. Clarification of the physiological role of 
endogenous vanilloids in meningeal tissues may provide 
further insights into the role of TRPV1 and CB1 receptors in 
the pathophysiology of the trigeminovascular system and 
headaches.  
IV. ANIMAL MODELS OF HEADACHES UTILIZING 
CAPSAICIN 
In animal experiments, capsaicin either applied directly 
onto the surface of the exposed dura mater in a rat open cra-
nial window preparation or injected intracisternally activates 
the trigeminovascular nociceptive afferents [12, 110]. Stimu-
lation of the trigeminal nociceptive nerve fibers with cap-
saicin activates face-grooming nociceptive behavior [111-
113], and induces changes in the blood flow of the menin-
geal tissues and neurochemical changes in second-order neu-
rons of the trigeminal brain stem nuclei. Animal models in-
volving capsaicin application are generally accepted as mod-
els of meningeal nociception and headache. 
The expression of c-fos protein induced experimentally 
within the TNC by chemical stimulation of the trigemino-
vascular system has been described. C-fos protein is a tran-
scription factor expressed by the immediate-early response 
of the c-fos gene and is a widely used marker of increased 
neuronal activity. Nociceptive stimulation of the dura mater 
with capsaicin or intracisternal capsaicin infusion increases 
the number of c-fos-like immunoreactive neurons within the 
TNC [114]. In these animal models, c-fos expression in lay-
ers I and II of the TNC is used to monitor the activation of 
the TNC. C-fos expression induced by capsaicin application 
was attenuated by pharmacological agents used for the 
treatment of migraine. In a conscious rat model of trigeminal 
nociception and cerebral c-fos expression, the pattern of 
brain activity could be demonstrated after noxious trigeminal 
stimulation with intracisternal capsaicin administration. The 
level of c-fos immunoreactivity was significantly increased 
in the TNC (layers I and II), the area postrema, the nucleus 
of the solitary tract, the parvicellular reticular nucleus, the 
locus coeruleus, the parabrachial nucleus and the raphe nu-
clei. In addition, the ventrolateral periaqueductal gray, and 
the intralaminar thalamic and various hypothalamic areas 
also displayed enhanced c-fos expression. Other responding 
areas were the amygdala, the upper lip and forelimb regions 
of the primary somatosensory cortex, and the insula [115]. 
The rat open cranial window model provides an opportu-
nity for the direct measurement of the blood flow changes 
induced by the activation of trigeminal nociceptive afferents. 
Application of capsaicin onto the exposed parietal dura ma-
ter induces a significant increase in meningeal blood flow as 
measured by laser Doppler flowmetry [12]. This effect is 
mediated by the activation of TRPV1 receptors, as evidenced 
by the inhibition of the response by capsazepine, a TRPV1 
receptor antagonist, and by prior systemic or local desensiti-
zation with capsaicin. Vasodilatation induced by the release 
of neuropeptides from activated trigeminal nerve endings 
may be a significant component of the pathophysiology of 
headaches probably involved in the fast elimination of proin-
flammatory agents from the meninges. 
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Animal models in which capsaicin is used as a nocicep-
tive stimulus provide a reliable experimental approach for 
study of the pathophysiological mechanisms activated in 
human headaches and to test the effects of pharmachological 
agents on meningeal nociceptive reactions [116,117].  
V. THE TRPV1-CGRP SYNAPSE 
1. The TRPV1 Receptor as a Target for Headache Ther-
apy 
The TRPV1 receptor is a molecular integrator of different 
physical and chemical noxious stimuli affecting sensory 
nerve endings. Pharmacological control of the TRPV1 recep-
tor function represents a new strategy for pain relief in head-
aches. Agonists of the TRPV1 receptor have a desensitizing 
and probably also a neurotoxic effect on chemosensitive 
primary sensory neurons [12, 15, 17, 18, 36, 118, 119]. 
TRPV1 receptor antagonists may interrupt the trigeminal 
transmission of sensory information and prevent the sensiti-
zation of nociceptive fibers that may occur in migraine.  
The blockade of CGRP receptors has recently been dem-
onstrated to serve as effective treatment for migraine attacks. 
Since a significant fraction of trigeminal ganglion neurons 
synthesizing the vasodilator neuropeptide CGRP are che-
mosensitive neurons expressing the TRPV1 receptor, CGRP 
receptor antagonists may act, at least partly, as inhibitors of 
the vasodilatation in dural blood vessels and the transmission 
of nociceptive impulses to the CNS induced by the activation 
of chemosensitive nerve fibers [120, 121].  
2. TRPV1 Antagonists  
Prolonged excitation of trigeminal primary afferents 
causing the sensitization of second-order neurons in the spi-
nal trigeminal nucleus can be inhibited by mechanisms 
which reduce the depolarization of sensory afferents and the 
release of neuropeptide and amino acid transmitters from 
their central terminals. Antagonists of the TRPV1 receptor 
have been sought because of their potential to interrupt the 
transmission of noxious signals from the periphery by pre-
venting neuropeptide release, the development of sensitiza-
tion and reversal of the effects of sensitization of second-
order neurons [122]. It has been observed that the expression 
of TRPV1 is increased in chronic pain states [123, 124], and 
it has been proposed that such increased expression plays a 
role in the development of trigeminal sensitization in head-
ache patients.  
TRPV1 antagonists are particularly potent and effica-
cious in preclinical pain models associated with low pH and 
thermal hyperalgesia, such as acute and chronic inflamma-
tion. The encouraging activity of SB-705498 (N-(2-
bromophenyl)-N′-[((R)-1-(5-trifluoromethyl-2-pyridyl) pyr-
rolidin-3-yl)] urea) in preclinical pain models prompted its 
subsequent clinical evaluation [125]. In experimental studies 
the i.v. administration of the TRPV1 receptor antagonist SB-
705498 induced a small, but significant suppression of sec-
ond-order neuronal responses to stimulation of both dura 
mater and facial skin afferents in rats. SB-705498 reversed 
and prevented the sensitization induced by the dural applica-
tion of „inflammatory soup” containing histamine, serotonin, 
bradykinin and prostaglandin E2 at pH 5.0 [122].  
These experimental results may be relevant both to the 
mechanisms of trigeminovascular sensitization and to the 
development of allodynia in some forms of migraine. It 
might also point the way to a therapeutic approach to prevent 
or reverse these symptoms when they occur. Clinical trials of 
SB-705498 to evaluate the efficacy in patients experiencing 
migraine have been completed, but the results have not yet 
been published. However, the use of TRPV1 antagonists 
may be limited by their effects in producing hyperthermia. 
The mechanisms of TRPV1 antagonist-induced hyperthermia 
include peripheral vasoconstriction that reduces heat loss and 
an increase in metabolic heat production measured by in-
creased oxygen consumption in rats. However, it is unclear 
whether presumed capsaicin-sensitive hypothalamic ther-
mosensitive neurons [126, 127] contribute to these ther-
moregulatory effects [128-130].  
3. TRPV1 Agonists  
Clinical studies of intranasal capsaicin administration 
have demonstrated its effectiveness in relieving cluster head-
aches. [131-133]. However, the initial application of the 
strongly irritant capsaicin is accompanied by an acute burn-
ing sensation, which is lost on repeated applications as the 
neurons become desensitized. This irritant property of cap-
saicin has limited its clinical use. Civamide (cis-8-methyl-N-
vanillyl-6-nonenamide), a synthetic isomer of capsaicin 
which is less irritating than capsaicin itself, acts as a TRPV1 
receptor agonist [134] that depletes the neurotransmitter con-
tent of capsaicin-sensitive nerve fibers and is significantly 
more potent than capsaicin at depleting CGRP and SP from 
sensory neurons. Civamide has been evaluated clinically as 
intranasal treatment for the relief of migraine headache 
[135]. Intranasal application of civamide solution reduced 
the number of cluster headache episodes, pain intensity and 
associated symptoms during and after the treatment, suggest-
ing the potential utility of TRPV1 receptor agonists for the 
prevention of cluster headache [136]. 
4. Substances Inhibiting Transmitter Release from Tri-
geminal Nerve Endings 
A variety of different prejunctional receptors located on 
the trigeminal sensory neurons may also regulate transmitter 
release upon activation. Transmitter release can be modified 
on both the peripheral and central terminals of primary sen-
sory neurons, inhibiting the local neurogenic inflammation 
and the excitation of the second-order neurons, respectively.  
5-hydroxytryptamine (5-HT1D,1F), α2-adrenoceptor, H3-
histamine, µ-opioid and somatostatin receptors have been 
identified on trigeminovascular afferent nerves [55, 137, 
138]. The inhibition of transmitter release mediated by these 
receptors may explain some success of somatostatin, adrena-
line or narcotics in the relief of headaches. Among the drugs 
acting on presynaptic receptors, only the 5-HT1D,1F receptor 
agonist triptans are widely and succesfully used in the ther-
apy of primary headaches. Triptans act on both the neuronal 
and the vascular 5-HT receptors, reducing neuropeptide re-
lease and blood flow in the pain-sensitive dura mater [139, 
140]. Sumatriptan as well as the newer triptans display high 
affinity at 5-HT1 receptor subtypes. They have high affinity 
for both 5-HT1B and 5-HT1D receptors, with sumatriptan be-
ing the weakest at the 5-HT1B and almotriptan the weakest at 
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the 5-HT1D receptor. The development of receptor subtype-
specific compounds and antibodies has allowed the precise 
identification of its vascular and neuronal sites of action, 
thereby providing a basis for the understanding of the patho-
physiology and a more precisely targeted therapeutic ap-
proach. 5-HT receptor subtypes are distributed differentially 
within the human trigeminovascular system. Vasoconstrictor 
responses to triptans are mediated by the vascular 5HT1B 
receptor [141-143]. 5-HT1D and 5-HT1F receptors are local-
ized in trigeminal sensory neurons, including the peripheral 
projections to the dura mater and the trigeminal nuclear 
complex and the solitary tract of the brainstem. These brain-
stem regions are known to possess binding sites for suma-
triptan and zolmitriptan, as detected by autoradiographic 
studies in rats and guinea pigs [144]. Selective 5-HT1D,1F 
receptor agonists may therefore decrease headaches by re-
ducing neuropeptide release, inhibiting neurogenic inflam-
mation in the dura mater and blocking neurotransmission, 
without the potential side-effects mediated through 5-HT1B 
receptor activation (i.e. vasoconstriction also in coronary and 
carotid arteries). Experimental results indicate that the vast 
majority of 5-HT1D-immunoreactive trigeminal neurons pos-
ses unmyelinated peptidergic axons that innervate the dura 
mater. In the TNC 5-HT1D-immunoreactive fibers are con-
centrated in Rexed laminae I and II, whereas a few axons 
penetrate into lamina V. 5-HT1D receptor immunoreactivity 
is found primarily within small-diameter, unmyelinated, pep-
tidergic nociceptors of the trigeminal ganglia. When 5-HT1D-
immunoreactive terminals in the superficial laminae of the 
TNC were examined at the electron microscopic level, it was 
found that the receptor concentrated in dense-core vesicles, 
which also contained SP [145]. The highly effective antimi-
graine potency of selective 5-HT1D and the putative 5-HT1F 
receptor agonists may be mediated, at least in part, by modu-
lation of the activity of capsaicin-sensitive meningeal affer-
ent nerves and also by inhibition of the release of SP and 
other vasoactive neuropeptides from capsaicin-sensitive no-
ciceptors. 
5. Non-peptide CGRP Receptor Antagonists 
CGRP plays a central role in the pathophysiology of 
headaches through its involvement in both the central and 
peripheral mechanisms of meningeal nociception. BIBN4096 
(olcegepant), which inhibits CGRP-induced vasodilatation, is 
the first non-peptide CGRP antagonist for migraine therapy 
that has been tested in clinical trials [120]. Olcegepant is 
well tolerated and effective in migraine attacks [121]. Its 
main limitation is its poor oral bioavailability, so that it has 
only been tested through i.v. administration. 
MK-0974 (telcagepant) is another non-peptide oral 
CGRP receptor antagonist that has been developed for the 
treatment of migraine [146]. This compound blocks CGRP 
receptors and may inhibit the dilatation of dural vessels and 
reduce neurotransmission in the CNS, resulting in pain relief. 
Telcagepant itself does not cause vasoconstriction. Data 
from clinical trials suggest that the value of telcagepant for 
the acute treatment of migraine is comparable with that of 
triptan compounds, including pain relief and freedom from 
pain for 2 hours. However, recent data revealed a potential 
hepatotoxicity risk when telcagepant was dosed daily, which 
may limit its applicability in migraine prevention [147, 148]. 
VI. CONCLUDING REMARKS 
Primary sensory neurons expressing the TRPV1/ 
capsaicin receptor, a molecular integrator of a variety of no-
ciceptive stimuli, play a fundamental role in pain sensation. 
Morphological and functional studies in the rat dura mater 
have disclosed a widespread system of capsaicin-sensitive 
TRPV1-immunoreactive nerve fibers and their contribution 
to meningeal vascular reactions. The meningeal neurogenic 
sensory vasodilator responses elicited by activation of the 
TRPV1 receptor are mediated by the release of CGRP from 
sensory nerves, which suggests that similar mechanisms may 
operate in humans during migraine attacks, when an in-
creased concentration of CGRP is measured in the jugular 
venous blood. Capsaicin-sensitive trigeminal afferent nerves 
also contribute to the vasodilatory responses induced by the 
activation of PAR-2, which may also sensitize meningeal 
afferent nerves. Demonstration of the colocalization of PAR-
2 and TRPV1 receptors in the meningeal axons lends further 
support to this mechanism. The neurogenic vasodilatation 
mediated by capsaicin-sensitive afferent nerves may serve a 
protective function through the elimination of inflammatory 
mediators from the meningeal tissue, a mechanism which 
may play a role in the resolution of headaches. Pathological 
conditions such as diabetes mellitus may compromise this 
protective mechanism. Indeed, the function of trigeminovas-
cular nociceptive neurons is impaired by diabetes mellitus 
through decreases in the expression of the TRPV1 receptor 
and the release of CGRP from the affected neurons.  
These observations indicate an important role of cap-
saicin-sensitive meningeal afferent nerves in the pathophysi-
ology of headaches and suggest that pharmacological ma-
nipulation of the TRPV1 receptor may offer a promising 
approach to the management of headaches. 
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